Recent clinical trials indicate that patients with advanced pancreatic cancer treated with an experimental daily medication lived twice as long as those receiving standard chemotherapy.
The promise of daraxonrasib
Pancreatic cancer is one of the most aggressive forms of cancer, responsible for nearly 500,000 deaths globally each year. Due to the subtlety of its early symptoms, most patients are diagnosed at a late stage, often after the disease has metastasized. Consequently, their average survival with conventional treatments generally spans just a few months.
More than 90 percent of pancreatic cancer cases are linked to mutations in the K-Ras gene, which codes for a protein promoting unchecked cell growth in the pancreas, ultimately leading to tumors.
In a groundbreaking trial, researchers from the Memorial Sloan Kettering Cancer Center in New York enrolled 500 patients with metastatic pancreatic cancer from North America, Europe, and Asia. One group received a daily pill of daraxonrasib, an experimental drug designed to specifically target the K-Ras protein, while the other underwent traditional chemotherapy infusions.
A pancreatic cancer drug has been called “transformative” after it doubled survival time among people with a particularly severe form of the condition. https://t.co/xxIBbVcFHE
– New Scientist (@newscientist) June 1, 2026
Presented at the recent meeting of the American Society of Clinical Oncology, the results surpassed expectations. Patients on daraxonrasib had an average survival of 13.2 months, compared to just 6.7 months for those on chemotherapy. The research team highlighted this as one of the most significant advancements in pancreatic cancer treatment in decades.
Minimal side effects
Even more encouraging is the fact that only 1 percent of participants taking daraxonrasib had to discontinue treatment due to side effects (mostly skin rashes), whereas 11 percent of those undergoing chemotherapy experienced similar issues.
The trial data has been submitted to the U.S. Food and Drug Administration (FDA), which may soon approve this compound for patients with metastatic pancreatic cancer who have become resistant to standard treatments.
Eileen O’Reilly’s team is looking ahead to assess the efficacy of daraxonrasib in combination with chemotherapy and other experimental compounds, as well as exploring its potential as an initial treatment option for this cancer type.
In related advancements, researchers had previously developed a test capable of diagnosing pancreatic cancer at an early stage, offering hope for earlier intervention.




